GVR Report cover Preimplantation Genetic Testing Market Size, Share & Trends Report

Preimplantation Genetic Testing Market Size, Share & Trends Analysis Report By Product, By Procedure, By Technology, By Application, By End-use, By Region, And Segment Forecasts, 2023 - 2030

  • Report ID: GVR-2-68038-854-1
  • Number of Pages: 180
  • Format: Electronic (PDF)
  • Historical Range: 2018 - 2021
  • Industry: Healthcare

Report Overview

The global preimplantation genetic testing market size was estimated at USD 753.60 million in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 7.0% from 2023 to 2030. Rising incidence of single gene, mitochondrial, and other gene-related disorders are attributed to increasing demand for preimplantation diagnosis and screening processes over the forecast period. According to the Florida Department of Health, about one in every 33 babies is diagnosed with a congenital disability in the U.S., affecting nearly 120,000 babies annually.

U.S. Preimplantation Genetic Testing Market size and growth rate, 2023 - 2030

Preimplantation genetic diagnosis (PGD) is implemented before the IVF workflow for a successful pregnancy. PGD is deployed in IVF cycles of women who have had several miscarriages or had last pregnancy with a chromosome abnormality. PGD can benefit couples who are at risk of hereditary disorders, positively influencing the market growth.

The concept of aneuploidy screening during PGD has enhanced IVF procedures. The introduction of aneuploidy testing in IVF centers identifies abnormal embryos, resulting in successful pregnancy rates. PGT for aneuploidy (PGT-A) is used to screen chromosomal information related to embryos such as the presence and correct number of chromosomes. Benefits of PGT-A, such as the increased chance of pregnancy, decreased miscarriage rate, and reduced time & number of IVF procedures to achieve pregnancy are expected to increase the adoption of these tests over the projected period.

Moreover, subsequent innovations in genetic diagnosis such as introducing PGT monogenic disease diagnosis (PGT-M), stimulate industrial growth. PGT-M focuses on the identification of Mendelian genetic disorders in embryos for addressing challenges of prenatal diagnosis as it precludes the chances of elective termination of pregnancy. The high accuracy of the PGT-M test to identify chromosomal abnormalities in embryos reduce the risk of having a child with an inherited condition.

Growing awareness about genetic techniques for the detection of chromosomal abnormalities and embryo screening for successful IVF holds growth prospects for this vertical over the forecast period. For instance, in April 2023, The Prelude Network and The HelpCureHD Foundation launched the More Than Infertility campaign to educate and increase awareness about IVF with preimplantation genetic testing (PGT) to reduce genetic disorders such as Huntington's disease in newborns.

Early detection of chromosomal diseases, which potentially reduces the number of people suffering from congenital diseases, reduces the number of offspring born with inherited chromosomal abnormalities. This can be attributed to the increased demand for PGT services in recent years. Moreover, the growing incidence of various gene-related disorders is anticipated to boost the demand for the genomic diagnosis market.

In addition, increasing adoption of IVF in combination with preimplantation genetic diagnosis (PGD) is also anticipated to witness significant demand as it is already recommended for couples undergoing IVF therapy because of infertility and advanced maternal age, which in turn is expected to have a positive effect on the market progress. Moreover, favorable initiatives undertaken by market players and service providers to promote IVF procedures are expected to increase the demand for preimplantation genetic testing.

Ethical acceptability and legal regulations by public entities impede the adoption rate of PGT services thereby hampering the growth. However, awareness regarding the health of fetuses among couples and expanding applications of PGD and Preimplantation Genetic Screening (PGS) collectively create opportunities for market progression.

Procedure Insights

The PGD segment accounted for the largest revenue share of around 77.0% in 2022 and is projected to grow at the fastest CAGR over the forecast period. Growing awareness among healthcare professionals as well as customers about genetic testing of a specific gene mutation is the major factor driving the segment's growth. The rising incidence of single gene diseases and translocation cases accompanied by effective delivery of NGS technology for genetic testing by market entities spurs growth. Preimplantation genetic diagnosis (PGD) services allow embryo examination to determine if it carries the specific gene mutation which helps reduce the incidences of genetic diseases among newborns.

On the other hand, PGS services enable the screening of embryos for chromosomal abnormalities. These services are suggested for couples with advanced reproductive age, multiple IVF cycles, and recurrent pregnancy loss. The PGS services segment is anticipated to showcase lucrative growth during the forecast period due to continuously rising demand and the efficacious evolution of IVF procedures. Moreover, a large number of IVF processes are conducted in high-capacity laboratories due to the presence of better facilities, which in turn enhance the quality of PGS services, thereby driving growth.

Product Insights

The reagent & consumables segment accounted for the largest revenue share of 49.5% in 2022 and is anticipated to grow at the fastest CAGR in the coming years. Increasing adoption of PGT in the IVF process is fueling the demand for reagents & consumables. Around 2.5 million IVF cycles are performed, which result in more ine than 500,000 delivery by using IVF, annually. Moreover, increasing adoption of technologically advanced tests such as next-generation sequencing, polymerase chain reaction, fluorescent in-situ hybridization, and others are expected to increase segment growth.

The instruments segment held the second-largest share of the preimplantation genetic testing market in 2022. Market players are continuously involved in developing novel genetic testing instruments with high-accuracy results. Moreover, an increasing number of hospitals and clinics offering IVF services are anticipated to drive the demand for novel instruments to perform PGT on the premises.

Technology Insights

The polymerase chain reaction (PCR) segment accounted for the largest revenue share of 39.6% in 2022. High market penetration and cost-effectiveness coupled with high accuracy of PCR tests are some of the key factors supporting the high market share of the segment. Moreover, PCR increases the probability to get a large number of copies of a particular stretch of the genome, which increase the chance of detection of any chromosomal abnormalities in the sample. PCR is a specific and sensitive technology that is suitable for all types of genetic diagnosis.

Next-generation sequencing (NGS) is expected to grow at the fastest CAGR during the forecast period. As next-generation sequencing tests provide higher accuracy, compared to others, and are capable of sequencing large amounts of DNA in less time. Moreover, technological advancements have expanded the range of NGS, and they can detect many additional chromosomal abnormalities.

Application Insights

The aneuploidy screening segment dominated the preimplantation genetic testing market with a revenue share of 25.7% in 2022 and is projected to grow at the fastest CAGR over the forecast period. Aneuploidy screening is mostly used to determine embryo quality in IVF. Moreover, the increasing adoption of aneuploidy screening and the introduction of novel products in the market is anticipated to drive segment growth. For instance, in September 2022, Eurofins Genoma launched preimplantation genetic testing for aneuploidy (PGT-A).

The HLA typing segment held the second-largest market share in 2022. The role of preimplantation genetic testing in embryo HLA typing for stem cell therapy and others increased the segment share. This is because hematopoietic stem cell transplantation from interconnected-matched donors results in higher survival rates as compared to unrelated donors.

End-use Insights

The hospital segment accounted for the highest revenue share of around 39.0% in 2022. High patient inflow, improved healthcare infrastructure, and the presence of public and private hospitals offering IVF services are some of the major factors driving the segment's growth. Mostly, couples who are seeking fertility treatment go to hospitals for further treatments, because of the highly advanced technology available at hospitals. In addition, the rise in research at hospitals is expected to increase testing rates in hospital settings. Moreover, the hospital segment is projected to experience the fastest growth in the coming years.

Global Preimplantation Genetic Testing Market share and size, 2022

The fertility centers segment held the second-largest share of the preimplantation genetic testing industry in 2022. Improvement of healthcare infrastructure in fertility centers and technological advancements in testing services are expected to drive the growth of the segment in the forthcoming years.

Regional Insights

Europe dominated the market and accounted for the largest revenue share of 34.8% in 2022, attributed to an increased number of late pregnancies expected to be IVFs. Also, liberal regulations in several countries in this region for aneuploidy screening and the presence of strong market players & service providers are anticipated to add potential avenues in the European PGT market.

Preimplantation Genetic Testing Market Trends, by Region, 2023 - 2030

Asia Pacific region is anticipated to experience growth at the fastest CAGR over the forecast period. China and Japan are major countries in the region that continue to create advancements in reproductive health along with other healthcare disciplines. The high adoption rate of IVF translates into increased usage of PGT in this region, and increasing awareness levels among people are expected to boost revenue generation in the regional market.

Moreover, emerging economies such as China & India and the presence of regulatory bodies to monitor challenges associated with reproductive health are expected to encourage the adoption of these services in this region in the near future. For instance, in November 2021, Peking Jabrehoo Med Tech Co. Ltd. received marketing approval from NMPA in China for its preimplantation genetic testing for aneuploidy.

Key Companies & Market Share Insights

Key players are adopting strategies such as new product launches, acquisitions, and collaborations to strengthen their presence in other regional markets. This can lead to improved product development, operational efficiencies, or expanded market reach. For instance, in July 2022, GenEmbryomics launched research using only whole genome sequencing tests to screen genetic diseases in IVF embryos. Some prominent players in the global preimplantation genetic testing market include:

  • Quest Diagnostics Incorporated

  • Natera, Inc.

  • COOPER SURGICAL, INC.

  • Genea Pty Limited.

  • Invitae Corporation

  • Laboratory Corporation of America Holdings

  • Thermo Fisher Scientific Inc.

  • Bioarray S.L.

  • Illumina, Inc.

  • Igenomix

  • RGI

  • F. Hoffmann-La Roche Ltd

Preimplantation Genetic Testing Market Report Scope

Report Attribute

Details

Market size value in 2023

USD 800.70 million

Revenue forecast in 2030

USD 1.28 billion

Growth rate

CAGR of 7.0% from 2023 to 2030

Base year for estimation

2022

Historical data

2018 - 2021

Forecast period

2023 - 2030

Report updated

August 2023

Quantitative units

Revenue in USD million/billion, CAGR from 2023 to 2030

Report coverage

Revenue forecast, company ranking, competitive landscape, growth factors, trends

Segments covered

Procedure, product, technology, application, end-use, region

Region scope

North America; Europe; Asia Pacific; Latin America; MEA

Country scope

U.S.; Canada; Germany; UK; France; Italy; Spain; Denmark; Sweden; Norway; China; Japan; India; Australia; South Korea; Thailand; Brazil; Mexico; Argentina; South Africa; Saudi Arabia; UAE; Kuwait

Key companies profiled

Quest Diagnostics Incorporated; Natera, Inc.; COOPER SURGICAL, INC.; Genea Pty Limited.; Invitae Corporation; Laboratory Corporation of America Holdings; Thermo Fisher Scientific Inc.; Bioarray S.L., Illumina, Inc.; Igenomix, RGI; F. Hoffmann-La Roche Ltd

Customization scope

Free report customization (equivalent up to 8 analyst working days) with purchase. Addition or alteration to country, regional & segment scope.

 

Global Preimplantation Genetic Testing Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2018 to 2030. For this report, Grand View Research has segmented the global preimplantation genetic testing market report based on procedure, product, technology, application, end-use, and region:

  • Procedure Outlook (Revenue, USD Million, 2018 - 2030)

    • PGD

    • PGS

  • Product Outlook (Revenue, USD Million, 2018 - 2030)

    • Reagents and Consumables

    • Instruments

    • Software

  • Technology Outlook (Revenue, USD Million, 2018 - 2030)

    • Next Generation Sequencing (NGS)

    • Polymerase Chain Reaction (PCR)

    • Fluorescent In-Situ Hybridization (FISH)

    • Others

  • Application Outlook (Revenue, USD Million, 2018 - 2030)

    • Chromosomal Abnormalities

    • X-linked Diseases

    • Embryo Testing

    • Aneuploidy Screening

    • HLA Typing

    • Other Applications

  • End-Use Outlook (Revenue, USD Million, 2018 -2030)

    • Fertility Centers

    • Hospitals

    • Diagnostic Centers

    • Research Centers and Academic Labs

  • Regional Outlook (Revenue, USD Million, 2018 - 2030)

    • North America

      • U.S.

      • Canada

    • Europe

      • UK

      • Germany

      • France

      • Italy

      • Spain

      • Denmark

      • Sweden

      • Norway

    • Asia Pacific

      • Japan

      • China

      • India

      • Australia

      • South Korea

      • Thailand

    • Latin America

      • Brazil

      • Mexico

      • Argentina

    • Middle East and Africa

      • South Africa

      • Saudi Arabia

      • UAE

      • Kuwait

Frequently Asked Questions About This Report

gvr icn

GET A FREE SAMPLE

gvr icn

This FREE sample includes data points, ranging from trend analyses to estimates and forecasts. See for yourself.

gvr icn

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now

Certified Icon

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.